Skip to main content
SleepCited

Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.

Stephen M Stahl
Review CNS spectrums 2014 13 citations

Study Design

Study Type
Review
Population
Totally blind individuals with non-24 sleep-wake syndrome
Intervention
Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
Primary Outcome
Non-24 sleep-wake syndrome in blind patients
Effect Direction
Positive
Risk of Bias
Unclear

Abstract

Many individuals with total blindness can develop a circadian rhythm disorder-called non-24 sleep wake syndrome-because they cannot detect light to resynchronize their sleep-wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.

TL;DR

A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in patients with total blindness, resetting their circadian sleep–wake clocks.

Used In Evidence Reviews

Similar Papers

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.